Research Paper
Generation of allo-restricted peptide-specific T cells using RNA-pulsed dendritic cells: A three phase experimental procedure
Downloads and Tools
Volume 1, Issue 2 March/April 2012
Pages 129 - 140
http://dx.doi.org/10.4161/onci.1.2.18216
Keywords: T cell receptor (TCR), TCR gene therapy, adoptive T cell therapy, dendritic cells, human cytotoxic T lymphocytes
Authors: Susanne Wilde, Christiane Geiger, Slavoljub Milosevic, Barbara Mosetter, Sabine Eichenlaub and Dolores J. Schendel
View affiliations Hide affiliations
- Susanne Wilde
-
Institute of Molecular Immunology; Helmholtz Zentrum München; German Research Center for Environmental Health; Munich, Germany
- Christiane Geiger
-
Institute of Molecular Immunology; Helmholtz Zentrum München; German Research Center for Environmental Health; Munich, Germany
- Slavoljub Milosevic
-
Institute of Molecular Immunology; Helmholtz Zentrum München; German Research Center for Environmental Health; Munich, Germany
- Barbara Mosetter
-
Institute of Molecular Immunology; Helmholtz Zentrum München; German Research Center for Environmental Health; Munich, Germany
- Sabine Eichenlaub
-
Institute of Molecular Immunology; Helmholtz Zentrum München; German Research Center for Environmental Health; Munich, Germany
- Dolores J. Schendel
-
Corresponding author: schendel@helmholtz-muenchen.de
Institute of Molecular Immunology; Helmholtz Zentrum München; German Research Center for Environmental Health; Munich, Germany; Clinical Cooperation Group ‘Immune Monitoring’; Helmholtz Zentrum München; German Research Center for Environmental Health; Munich, Germany
Abstract:
Designer T cells expressing transgenic T cell receptors (TCR) with anti-tumor specificity offer new treatment options for cancer patients. We developed a three phase procedure to identify T cells of high avidity based on the fact that T cells recognizing peptides presented by allogeneic MHC efficiently kill tumor cells. Autologous dendritic cells (DC) are co-transfected with ivt-RNA encoding an allogeneic MHC molecule and a selected antigen to allow them to express allogeneic MHC-peptide complexes that activate allo-restricted peptide-specific T cells. This approach provides great flexibility for obtaining high-avidity T cells as potential sources of TCR for adoptive T cell therapy.
Received: September 23, 2011; Accepted: September 26, 2011
Preview: